Daniel J. George, MD, highlights emerging trials such as PEACE III that further explore the use of radium-223 in prostate cancer and reinforce important variables in managing patients with metastatic castration-resistant prostate cancer (mCRPC).

For more resources and information regarding anticancer targeted therapies: [ Ссылка ]

свернуть